ZHI Technologies Inc. Launches Patented
Clinically Validated Transdermal Platform, Entering Scalable Commercial Growth Phase
Fort Lauderdale, FL — April 23, 2026
ZHI Technologies Inc. today announced the commercial launch of its proprietary transdermal patch platform, backed by issued patents and validated through multiple clinical studies, marking the company’s transition from development-stage innovation to active revenue-generating operations.
Designed to deliver consistent, controlled-release absorption of active ingredients through the skin, ZHI’s platform offers a non-invasive alternative to traditional oral and injectable delivery methods, addressing key challenges around bioavailability, consistency, and user experience. These outcomes are supported by completed clinical studies demonstrating reliable pharmacokinetic performance and improved delivery efficiency versus conventional formats.
Following years of development, capital investment, and manufacturing buildout, ZHI is now actively selling finished products and entering a new phase of scalable commercial growth.
Built for Scale
ZHI’s platform has been engineered for consistency, scalability, and repeatable performance. The company operates from a cGMP ISO 7 controlled manufacturing environment in Fort Lauderdale, Florida, enabling it to support current demand while positioning for future expansion across multiple product categories.
The platform is protected by issued patents and additional filings covering its controlled-release and permeation-enhancing technology, creating a strong barrier to entry and long-term competitive advantage.
Commercial Product Portfolio
ZHI’s initial product line includes:
CBD (Cannabidiol): supporting balance and daily wellness
CBN (Cannabinol): designed for sleep and recovery
CBG (Cannabigerol): supporting focus and daytime function
Lidocaine: targeted localized pain relief
These products are designed to deliver consistent, controlled-release absorption, offering a superior alternative to traditional delivery formats.
Clinical Validation & Intellectual Property
ZHI has completed multiple human clinical studies across its cannabinoid product line, including CBD and CBN formulations, demonstrating consistent absorption, predictable delivery profiles, and improved bioavailability.
The company’s platform is supported by patented technology and additional intellectual property filings covering its proprietary transdermal delivery system, positioning ZHI as a leader in next-generation non-invasive drug delivery systems.
Leadership Commentary
“This launch represents the culmination of years of disciplined execution, significant capital investment, and a clear focus on building a scalable delivery platform supported by clinical validation and protected intellectual property,” said Robert C. Galler, CEO of ZHI Technologies.
“We are now operating commercially, with finished products in market and infrastructure in place to support meaningful growth. Our focus moving forward is scaling production, expanding distribution, and leveraging our platform across multiple applications, including regulated pharmaceutical pathways.”
Growth Outlook
With commercial operations now underway, ZHI is focused on expanding production capacity, increasing distribution channels, and continuing to develop new applications leveraging its controlled-release transdermal delivery systems.
The company intends to leverage its clinical data and patent portfolio to pursue regulated pharmaceutical pathways, including potential 505(b)(2) applications, while also expanding within the wellness and performance markets.
ZHI is well-positioned to participate in the growing demand for non-invasive, consistent delivery technologies across both consumer and medical sectors.
Now Available Online
ZHI products are now available for purchase. Consumers and partners can explore the platform and product line at: www.zhitechnologies.com
About ZHI Technologies
ZHI Technologies is a Florida-based company focused on the development and manufacturing of patented, clinically validated controlled-release transdermal delivery systems. Its platform enables consistent, non-invasive delivery of active ingredients across a range of wellness and therapeutic applications, with future expansion into regulated pharmaceutical markets.
Media Contact
Ready to experience 24-hour relief?
Shop our CBD, CBN, CBG, and Lidocaine transdermal patches today and discover the ZHI difference.
Disclaimer
The statements made regarding these products have not been evaluated by the Food and Drug Administration. The efficacy of these products has not been confirmed by FDA-approved research. These products are not intended to diagnose, treat, cure or prevent any disease. All information presented here is not meant as a substitute for or alternative to information from health care practitioners. Please consult your health care professional about potential interactions or other possible complications before using any product. The Federal Food, Drug, and Cosmetic Act require this notice.
Copyright © 2026 | ZHI Technologies